98%
921
2 minutes
20
Objective: To evaluate cost-effectiveness and user satisfaction of a single-use flexible cystoscope at a tertiary care center we conducted a 90-day trial. Single-use flexible cystoscope advancements have introduced alternative options to reusable scopes. However, there is a paucity of cost-effectiveness and provider satisfaction studies examining the implementation of a hospital-based transition to single-use cystoscopes.
Methods: Following institutional device-approval we initiated a 90-day trial period (November 1, 2020-January 29, 2021) where all flexible, transurethral, and percutaneous, urologic care was provided with a disposable AMBU aScope. We performed a micro-costing analysis examining payor per case cost of the reusable flexible cystoscope (including servicing and processing) to the disposable units. Provider surveys assessed visual quality, deflection, ease of working channel and overall satisfaction on a 10-point Likert scale.
Results: Over the 90-day period, we encountered 84 cases (78 operative, 5 inpatient, 1 emergency department) where flexible cystoscopy was required. One disposable flexible cystoscope was successfully used in 78 of 84 (93%) cases. Of the 6 failures, 2 were due to an inability to access a disposable scope/monitor. Per use cost of the reusable flexible cystoscope at our center was $272.41 versus $185.00 for the single use. Extrapolating our average case volume and conservative failure rate (3 single use failures/month, requiring reusable), transitioning to predominately single use scopes results in $39,142.84 annual cost savings.
Conclusions: This single center 90-day trial of disposable flexible cystoscopy identified per-use costs to be less when a single-use flexible cystoscope was utilized at a high-volume tertiary care center.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.urology.2022.05.039 | DOI Listing |
J Endourol
July 2025
Department of Urology, University of Trieste, Trieste, Italy.
To evaluate the feasibility, safety, and patient satisfaction of Double-J (DJ) ureteral stenting using a flexible cystoscope under local anesthesia (LA). We analyzed prospectively collected data from all patients who underwent DJ stent insertion or replacement using flexible single-use cystoscope under LA between February 2022 and September 2024 at two tertiary referral centers. Failure was defined as the inability to effectively complete the scheduled stent insertion or replacement.
View Article and Find Full Text PDFUrology
July 2025
Division of Urology, University of Toronto, Toronto, Ontario, Canada; Department of Urology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Electronic address:
Objective: To reintroduce the versatility of the pediatric cystoscope, we aimed to synthesize the origins of ureteroscopy and outline our experience utilizing the instrument for the diagnosis and treatment of ureteral pathology.
Methods: We reviewed published literature for historical and modern-day uses of the pediatric cystoscope for ureteroscopy. In addition, we described our experience maneuvering the scope in common patient scenarios and use this to discuss the pros and cons of this tool for ureteroscopy.
Can Urol Assoc J
July 2025
Unité d'évaluation des technologies et des modes d'intervention en santé (UETMIS), Centre Hospitalier Universitaire de Québec-Université Laval (CHU de Québec), Quebec, QC, Canada.
Introduction: This study conducts a budget impact analysis to evaluate the cost of removing double J catheters using single-use flexible digital cystoscopes compared to reusable cystoscopes at the CHU de Québec.
Methods: The UETMIS of CHU de Québec estimated average costs per intervention for both reusable and single-use flexible cystoscopes in the endoscopy room. Costs included purchase, repair, reprocessing, and sterilization for reusable cystoscopes based on data from 2017-2019.
J Endourol
July 2025
Department of Urology, University Hospital Southampton, Southampton, UK.
To evaluate the indications and clinical outcomes of local anesthetic stenting in urological procedures, assessing its effectiveness, adverse effects, and patient tolerance. The systematic review was conducted in line with Cochrane and Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. MEDLINE, CINAHL, EMBASE, and the Cochrane Central Register were searched up to September 2024 (PROSPERO-CRD42024596866).
View Article and Find Full Text PDFProstate Cancer Prostatic Dis
May 2025
Department of Urology, Northwell Health, New York, NY, USA.
Introduction: This study aimed to evaluate the feasibility and safety of the FloStent™, a novel nitinol prostatic stent, in men with LUTS secondary to BPH.
Materials And Methods: This multi-center, single-arm, one-year study included men aged ≥45 with BPH. Participants underwent FloStent™ implantation using a flexible cystoscope.